Active in more than 30 countries
As part of the German pharmaceutical company Boehringer Ingelheim, the Boehringer Ingelheim Regional Center Vienna (RCV for short) bears business responsibility for more than 30 countries in Central and Eastern Europe and Central Asia. This makes RCV one of the Group's most important sites and also a flagship operation in the Austrian capital, where more than 3,000 people are employed.
Boehringer Ingelheim RCV GmbH & Co KG is one of the most important sites within the global group of companies. Vienna is the center of Boehringer Ingelheim's cancer research. Another focus is on the development and production of biopharmaceutical drugs, which we also manufacture for third-party suppliers.
As a Regional Center, we are not only responsible for the Austrian market, but also serve a total of 33 countries - from Central and Eastern Europe to Russia, Mongolia and Israel.
Together, we pursue one goal: to achieve breakthroughs in the treatment of diseases and to advance the development of medicine.
Vienna is different, Vienna is better
Vienna was at the beginning of our expansion: the establishment of the site in 1948 was the first step in Boehringer Ingelheim's internationalization. We continue to invest massively in the site. This benefits not only the company, but also Vienna through high added value and the creation of attractive jobs.
Boehringer Ingelheim - a global presence
Boehringer Ingelheim is one of the 20 leading pharmaceutical companies worldwide. Headquartered in Ingelheim, Germany, Boehringer Ingelheim is represented worldwide by 145 affiliated companies. We are a stable employer for more than 50,000 employees worldwide. In the last 10 years alone, we have grown by around 10,000 employees.
Founded in 1885, the family-owned company focuses on drug discovery and the development, production and sale of new medicines with high therapeutic value for human and animal health.
Related Content
Fact & Figures Boehringer Ingelheim RCV
Our Countries
